Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 15, 2025
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 15, 2025
Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026 Published positive data from its global Phase 2 …
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
GlobeNewswire
·
May 15, 2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
GlobeNewswire
·
May 15, 2025
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24) …
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 15, 2025
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related …
CytoDyn Releases ESMO Breast Cancer Meeting Poster
GlobeNewswire
·
May 15, 2025
VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today shared the …
IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19
GlobeNewswire
·
May 15, 2025
Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential applications in COVID-19 and other infectious diseases with …
Retrospective Analysis of U.S. Claims Data Shows AUVI-Q® (epinephrine injection, USP) Prescription Associated with Lower Rates of Anaphylaxis-Related Inpatient Hospitalizations Compared to Other Epinephrine Auto-Injectors
GlobeNewswire
·
May 15, 2025
Richmond, Virginia, May 15, 2025 (GLOBE NEWSWIRE) -- New findings from a retrospective analysis of U.S. commercial claims data indicate that patients prescribed AUVI-Q® (epinephrine injection, USP) experienced lower rates of inpatient hospitalization for …
Legend Senior Living Names Robert Fries as Vice President of Operations
GlobeNewswire
·
May 15, 2025
WICHITA, Kan., May 15, 2025 (GLOBE NEWSWIRE) -- Legend Senior Living, a leading senior living owner/operator based in Wichita, KS, has announced Robert Fries as their Vice President of Operations in Pennsylvania. Fries will oversee all aspects of …
Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025
GlobeNewswire
·
May 15, 2025
SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a …
First Procedures Completed with EndoQuest’s Endoluminal Surgical System in PARADIGM Trial
GlobeNewswire
·
May 15, 2025
Houston, TX, May 15, 2025 (GLOBE NEWSWIRE) -- EndoQuest Robotics, Inc., a pioneering leader in the development of endoluminal robotic surgical technology, announced today the completion of the first procedures of its pivotal clinical trial, Prospective …
American Oncology Network Appoints Joe Verschleiser as Chief Growth and Performance Officer
GlobeNewswire
·
May 15, 2025
FORT MYERS, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing community oncology networks, today announced the appointment of Joe Verschleiser as chief growth and performance officer. “We are …
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision Pediatric cohort of LCA5 study ongoing with initial multi-patient data anticipated in Q3 2025 OPGx-BEST1 on …
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 15, 2025
FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that the company …
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
GlobeNewswire
·
May 15, 2025
Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1–resistant tumors Near-term capital transactions poised to bolster liquidity NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. ( …
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 …
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 15, 2025
PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force PEMGARDA revenue re-acceleration observed in Q2 2025 to date Invivyd continues to …
EDAP Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 15, 2025
Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled …
Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer
GlobeNewswire
·
May 15, 2025
Two independent Phase 2 trials demonstrate extended progression-free survival in patients without TP53 mutations or without liver metastases Results presented at 2025 ESMO Breast Cancer Annual Congress BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Carrick …
AAFA Calls for Comprehensive Reform to Make Medicines Accessible and Affordable for All
GlobeNewswire
·
May 15, 2025
Washington, DC, May 15, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) appreciates the President’s Executive Order calling attention to America’s persistent problem of unaffordable prescription medicines. Our research tells us …
I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 15, 2025
Prioritization of givastomig as I-Mab’s lead program positions the Company for clinical progress New givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in Barcelona, Spain Strong financial position supported by …